Clinical update on the use of immuno modulators (AntiCD3, GAD, Diapep277, anti-IL1) in type 1 diabetes

Current Pharmaceutical Design

Volumn 17, Issue 29, 2011, Pages 3224-3228

  Pozzilli, Paolo ^a,b   Guglielmi, Chiara ^a   Maggi, Daria ^a   Carlone, Angela ^c   Buzzetti, Raffaella ^c   Manfrini, Silvia ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

^b QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^c SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

Anti CD3; Anti IL1 receptor antagonist; Autoimmunity; Diapep 277; GAD; Immuno intervention; Immuno tolerance; Type 1 diabetes

Indexed keywords

AUTOANTIGEN; CD3 ANTIBODY; DIAPEP277; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 65 ANTIBODY; IMMUNOMODULATING AGENT; OTELIXIZUMAB; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG; CD3 ANTIGEN; CHAPERONIN; DIAPEP 277; IMMUNOLOGIC FACTOR; INTERLEUKIN 1 RECEPTOR; PEPTIDE FRAGMENT;

DRUG ACTIVITY; FEVER; GASTROINTESTINAL SYMPTOM; HEADACHE; HUMAN; IN VITRO STUDY; IN VIVO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; RASH; REVIEW; ANIMAL; DRUG ANTAGONISM; DRUG DESIGN; GLUCOSE BLOOD LEVEL; IMMUNOLOGY; METABOLISM; T LYMPHOCYTE;

ANIMALS; ANTIGENS, CD3; BLOOD GLUCOSE; CHAPERONIN 60; DIABETES MELLITUS, TYPE 1; DRUG DESIGN; GLUTAMATE DECARBOXYLASE; HUMANS; IMMUNOLOGIC FACTORS; INSULIN-SECRETING CELLS; PEPTIDE FRAGMENTS; RECEPTORS, INTERLEUKIN-1; T-LYMPHOCYTES;

EID: 84858744139     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161211798157531     Document Type: Review

References (54)

1. Winer S, Tsui H, Lau A, et al. Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive. Nat Med 2003; 9:198-205
2. Bonifacio E, Ziegler AG. Advances in the prediction and natural history of type 1 diabetes. Endocrinol Metab Clin North Am 2010; 39:513-525
3. Petrone A, Galgani A, Spoletini M, et al. Residual insulin secretion at diagnosis of type 1 diabetes is independently associated with both, age of onset and HLA genotype. Diabetes Metab Res Rev 2005; 21:271-275
4. Leslie RD, Williams R, Pozzilli P. Clinical review: type 1 diabetes and latent autoimmune diabetes in adults: one end of the rainbow. J Clin Endocrinol Metab 2006; 91:1654-1659
5. Maahs DM, West NA, Lawrence JM, et al. Epidemiology of type 1 diabetes. Endocrinol Metab Clin North Am 2010; 39:481-497
6. Patterson CC, Dahlquist GG, Gyürüs E, et al. Incidence trends for childhood type 1 diabetes in Europe during 1989-2003 and predicted new cases 2005-20: a multicentre prospective registration study. Lancet 2009; 373:2027-2033
7. Pozzilli P, Buzzetti R. A new expression of diabetes: double diabetes. Trends Endocrinol Metab 2007; 18:52-57
8. Pozzilli P, Leslie RD. New prospects for immunotherapy at diagnosis of type 1 diabetes. Diabetes Metab Res Rev 2009; 25:299-301
9. van Belle TL, Coppieters KT, von Herrath MG. Type 1 diabetes: etiology, immunology, and therapeutic strategies. Physiol Rev 2011; 91:79-118
10. Cernea S, Raz I, Herold KC, et al. D-Cure Workshop. Challenges in developing endpoints for type 1 diabetes intervention studies. Diabetes Metab Res Rev 2009; 25:694-704
11. Pozzilli P, Visalli N, Buzzetti R, et al. Metabolic and immune parameters at clinical onset of insulin dependent diabetes: a population-based study. IMDIAB Study group. Immunotherapy Diabetes. Metabolism 1998; 47:1205-1210
12. The Canadian-European randomized control trial group. Cy-closporin-induced remission of IDDM after early intervention: association of 1 year of cyclosporin treatment with enhanced insulin secretion. Diabetes 1988; 37:1574-1582
13. Pozzilli P, Visalli N, Signore A, et al. Double blind trial of nicoti-namide in recent-onset IDDM (the IMDIAB III study). Diabetolo-gia 1995; 38:848-852
14. Harris SS. Vitamin D in type 1 diabetes prevention. J Nutr 2005; 135:323-325
15. Bizzarri C, Pitocco D, Napoli N, et al. No protective effect of cal-citriol on beta-cell function in recent-onset type 1 diabetes: the IMDIAB XIII trial. Diabetes Care 2010; 33:1962-1963
16. Walter M, Kaupper T, Adler K, et al. No effect of the 1alpha,25-dihydroxyvitamin D3 on beta-cell residual function and insulin requirement in adults with new-onset type 1 diabetes. Diabetes Care 2010; 33:1443-1448
17. Giannoukakis N. DiaPep277 (DeveloGen). Curr Opin Investig Drugs 2005; 6:1043-1050
18. Wallin RP, Lundqvist A, Moré SH, et al. Heat-shock proteins as activators of the innate immune system. Trends Immunol 2002; 23:130-135
19. Quintana FJ, Cohen IR. HSP60 speaks to the immune system in many voices. Novartis Found Symp 2008; 291:101-111
20. Quintana FJ, Cohen IR. The HSP60 immune system network. Trends Immunol 2011; 32:89-95
21. Raz I, Elias D, Avron A, et al. Beta-cell function in new onset type 1 diabetes and immunomodulation with a heat-shock protein pep-tide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001; 358:1749-1753
22. Eldor R, Kassem S, Raz I. Immune modulation in type 1 diabetes mellitus using DiaPep277: a short review and update of recent clinical trial results, Diabetes Metab Res Rev 2009; 25:316-320
23. Bolt S, Routledge E, Lloyd I, et al. The generation of a humanized, non mitogenic CD3 monoclonal antibody which retains in vitro immunosuppressive properties. Eur J Immunol 1993; 23:403-411
24. Herold KC, Burton JB, Francois F, et al. Activation of human T cells by FcR nonbinding anti-CD3 mAB, hORT3gamma1 (Ala-Ala). J Clin Invest 2003; 111:409-418
25. Vossen AC, Tibbe GJ, Kroos MJ, et al. Fc receptor binding of anti-CD3 monoclonal antibodies is not essential for immunosuppres-sion, but triggers cytokine-related side effects. Eur J Immunol 1995; 25:1492-1496
26. Von Essen M, Bonefeld CM, Siersma V, et al. Constitutive and ligand-induced TCR degradation. J Immunol 2004; 173:384-393
27. Liu H, Rhodes M, Wiest DL, et al. DA. On the dynamics of TCR:CD3 complex cell surface expression and downmodulation. Immunity 2000; 13:665-675
28. Smith JA, Tso JY, Clark MR, et al. Nonmitogenic anti-CD3 monoclonal antibdies deliver a partial T cell receptor signal and induce clonal anergy. J Exp Med 1997; 185:1413-1422
29. Smith JA, Tang Q, Bluestone JA. Partial TCR signals delivered by FcR nonbinding anti-CD3 monoclonal antibodies differentially regulate individual Th subsets. J Immunol 1998; 160:4841-4849
30. Herold KC, Hagopian W, Auger JA, et al. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N.Engl J Med 2002; 346:1692-1698
31. Keymeulen B, Vandemeulebroucke E, Ziegler AG, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005; 352:2598-2608
32. Featherstone DE, Rushton EM, Hilderbrand-Chae M, et al. Presyn-aptic glutamic acid decarboxylase is required for induction of the postsynaptic receptor field at a glutamatergic synapse. Neuron 2000; 27:71-84
33. Ludvigsson J. Therapy with GAD in diabetes. Diabetes Metab Res Rev 2009; 25:307-315
34. Mehta AK, Ticku MK. An update on GABAA receptors. Brain Res Brain Res Rev 1999; 29: 196-217
35. Björk E, Kämpe O, Karlsson FA, et al. Glucose regulation of the autoantigen GAD65 in human pancreatic islets. J Clin Endocrinol Metab 1992; 75:1574-1576
36. Hawa MI, Leslie RD. GAD antigen and its significance in type I diabetes. J Endocrinol Invest 2002; 25:576
37. Tisch R, Liblau RS, Yang XD, et al. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nono-bese diabetic mice. Diabetes 1998; 47:894-899
38. Ludvigsson J, Faresjö M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008; 359:1909-1920
39. Chéramy M, Skoglund C, Johansson I, et al. GAD-alum treatment in patients with type 1 diabetes and the subsequent effect on GADA IgG subclass distribution, GAD65 enzyme activity and humoral response. Clin Immunol 2010; 137:31-40
40. Dinarello C, Arend W, Sims J, et al. IL-1 family nomenclature. Nat Immunol 2010; 11: 973
41. Flannery S, Bowie AG. The interleukin-1 receptor-associated kinases: critical regulators of innate immune signalling. Biochem Pharmacol 2010; 80:1981-1991
42. Gabay C, Lamacchia C, Palmer G. IL-1 pathways in inflammation and human diseases. Nat Rev Rheumatol 2010; 6:232-241
43. Mandrup-Poulsen T, Pickersgill L, Donath MY. Blockade of inter-leukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 2010; 6:158-166
44. Glaser B. Type 2 diabetes: hypoinsulinism, hyperinsulinism, or both? PLoS Med 2007; 4:148
45. Butler AE, Janson J, Bonner-Weir S, et al. Beta-cell deficit and increased beta-cell apoptosis in humans with type 2 diabetes. Diabetes 2003; 52:102-110
46. Kolb H, Mandrup-Poulsen T. An immune origin of type 2 diabetes? Diabetologia 2005; 48:1038-1050
47. Maedler K, Sergeev P, Ehses JA, et al. Leptin modulates beta cell expression of IL-1 receptor antagonist and release of IL-1beta in human islets. Proc Natl Acad Sci USA 2004; 101:8138-8143
48. Arnush M, Heitmeier MR, Scarim AL, et al. IL-1 produced and released endogenously within human islets inhibits beta cell function. J Clin Invest 1998; 102:516-526
49. Maedler K, Schulthess FT, Bielman C, et al. Glucose and leptin induce apoptosis in human beta-cells and impair glucose-stimulated insulin secretion through activation of c-Jun N-terminal kinases. FASEB J 2008; 22:1905-1913
50. Reiner AP, Wurfel MM, Lange LA, et al. Polymorphisms of the IL1-receptor antagonist gene (IL1RN) are associated with multiple markers of systemic inflammation. Arterioscler Thromb Vasc Biol 2008; 28:1407-1412
51. Larsen CM, Faulenbach M, Vaag A, et al. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. Diabetes Care 2009; 32:1663-1668
52. Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med 2007; 356:1517-1526.
53. Skyler JS. Type 1 Diabetes TrialNet Study Group. Update on worldwide efforts to prevent type 1 diabetes. Ann N Y Acad Sci 2008; 1150:190-196.
54. Brown A, Reynolds LR, Bruemmer D. Intensive glycemic control and cardiovascular disease: an update. Nat Rev Cardiol 2010; 7:369-375.